Welcome to our dedicated page for PFIZER SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PFIZER's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PFIZER's regulatory disclosures and financial reporting.
BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Chairman & CEO Albert Bourla received a grant of 24.0000 Phantom Stock Units SSP on July 31, 2026 under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. Each unit represents one phantom share of common stock and is settled in cash after separation from service, increasing his reported phantom unit balance to 786154.0000.
BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Chairman & CEO Albert Bourla received a grant of 24 Phantom Stock Units SSP on July 15, 2026, at a reported transaction price of $24.82 per unit. Each unit represents one phantom share of common stock under Pfizer's Nonfunded Deferred Compensation and Supplemental Savings Plan.
The phantom units are settled in cash after Bourla's separation from service and may be transferred into an alternative investment account at any time. Following this grant, he holds 772,901 phantom stock units directly under the plan.
Pfizer Inc. Chairman & CEO Albert Bourla reported a compensation-related award of 84 Phantom Stock Units linked to Pfizer common stock on July 9, 2026. The units, valued at $24.25 per unit on the grant date, increase his directly held phantom stock balance to 772,938 units. These units were acquired under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan and are settled in cash following his separation from service.
BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Chairman and CEO Albert Bourla received a routine compensation grant of 25 Phantom Stock Units under the company’s Nonfunded Deferred Compensation and Supplemental Savings Plan. Each unit represents one phantom share of common stock and is settled in cash after his separation from service.
Following this award, Bourla holds a total of 772,979 phantom stock units. These units are a cash-settled, non-trading derivative tied to Pfizer’s common stock value and can be moved into an alternative investment account at his discretion, rather than being bought or sold on the open market.
Buckley Mortimer J reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Mortimer J. Buckley reported a compensation-related grant of 1,543.845 Phantom Stock Units tied to Pfizer common stock. The grant is priced at $24.29 per unit and represents deferred director compensation, including dividend equivalents.
According to the disclosure, these units will be settled in cash or common stock, at the director’s election, following his retirement from the Board of Directors. After this grant, Buckley now holds a total of 26,335.128 Phantom Stock Units directly. This filing reflects non‑market, derivative-based compensation rather than an open‑market share purchase or sale.
Pfizer Inc. director Joseph Echevarria received a grant of phantom stock units as deferred compensation. On this award date, he acquired 1,904.076 phantom stock units at a reference price of $24.2900 per unit, each unit representing one phantom share of common stock.
The units reflect deferred director compensation, including dividend equivalents, and will be settled in cash or Pfizer common stock at his election after he retires from the Board. Following this grant, his balance in these phantom stock units increased to 165,631.508 units, indicating this is part of an ongoing deferred compensation program rather than an open-market trade.
NARAYEN SHANTANU reported acquisition or exercise transactions in this Form 4 filing.
Pfizer director Shantanu Narayen reported a new compensation grant linked to company stock. He received 2,058.460 Phantom Stock Units on June 26, 2026 at a reference value of $24.29 per unit, bringing his total Phantom Stock Unit balance to 200,879.336 units.
Each unit represents one phantom share of Pfizer common stock and reflects deferred director compensation, including dividend equivalents. According to the disclosure, these units will be settled in cash or common stock, at Narayen’s election, after he retires from Pfizer’s Board of Directors.
SMITH JAMES C reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director James C. Smith received a grant of 1,852.614 Phantom Stock Units tied to Pfizer common stock. The units were awarded at a reference price of $24.2900 per unit and increase his phantom stock balance to 182,886.001 units.
According to the disclosure, these units represent deferred director compensation, including dividend equivalents, and will be settled in cash or common stock at his election after he retires from the Board of Directors. This is a compensation-related, non‑market transaction rather than an open‑market purchase or sale of Pfizer shares.
Quincey James reported acquisition or exercise transactions in this Form 4 filing.
Pfizer director James Quincey received a grant of 1,595.307 Phantom Stock Units linked to Pfizer common stock. The units were valued at $24.29 each and increase his deferred Phantom Stock Unit balance to 87,993.957 units following the transaction.
Each unit represents one phantom share of common stock and forms part of deferred director compensation, including dividend equivalents. These amounts are to be settled in cash or common stock, at the director's election, after he retires from Pfizer’s Board of Directors.
Taraporevala Cyrus reported acquisition or exercise transactions in this Form 4 filing.
Pfizer director Cyrus Taraporevala received a compensation-related award of phantom stock units. On this date, he was granted 1,543.845 Phantom Stock Units linked to Pfizer common stock at a reference price of $24.29 per unit.
Each unit represents one phantom share of common stock and is part of deferred director compensation, including dividend equivalents. These units will be settled in cash or common stock, at the director’s election, after he retires from Pfizer’s Board. Following this award, his balance of phantom stock units stands at 36,941.287.